IL6R and Myocardial fibrosis: However, therapeutic strategies aimed at reducing myocardial fibrosis and inflammation are emerging in the form of tocilizumab (an IgG1 subclass humanized anti-human interleukin-6 receptor antibody)32 and interleukin-1 inhibitors.33